retatrutide triple agonist glp-1 gip glucagon receptor The TRIUMPH-1 Phase 3 results just dropped on retatrutide. Here is what the numbers actually say. is a agonist. It targets GLP-1, GIP, and receptors. Ozempic targets one. Mounjaro Glucagon-like peptide-1 receptor agonists in

While the former was primarily managed with insulin or metformin to control glucose levels, the latter was often treated with lifestyle interventions or less effective pharmacotherapy

In liver disease, semaglutide received FDA accelerated approval in August 2025 for metabolic dysfunction-associated steatohepatitis in adults with moderate-to-advanced fibrosis

How have Medicaid prescriptions and gross spending on GLP-1s changed in recent years

If you mean: investigational drug most likely to reset expectations again the answer is retatrutide

Unlike oral semaglutide, which must be taken fasting with limited water, orforglipron can be taken at any time of day without food or water restrictions

For individuals with diabetes, a combined creatinine/cystatin C estimate of eGFR should be considered in settings where the creatinine-based eGFR may be unreliable for an individual (see Table 6) [21] [Grade D, Consensus]